IFT172: A Potential Drug Target and Biomarker for Intraflagellar Transport (IFT)

Target Name: IFT172

NCBI ID: G26160

IFT172

IFT172: A Potential Drug Target and Biomarker for Intraflagellar Transport (IFT)

Intraflagellar transport (IFT) is a protein that plays a crucial role in the transport of organelles, including mitochondrial organelles, to the endoplasmic reticulum (ER) in eukaryotic cells. The defect in IFT has been implicated in various diseases, including neurodegenerative disorders, myopathies, and cancer. Therefore, the discovery of a potential drug target and biomarker for IFT has significant implications for the development of new therapeutic approaches. IFT172 is one of the most promising candidates for a drug target and biomarker in this field.

Clinical Significance of IFT172

IFT is a transmembrane protein that consists of two subunits, IFTT1 and IFTT2. It plays a vital role in the transport of mitochondrial organelles, including the endoplasmic reticulum, to the cytoplasm. IFTT1 is the alpha subunit, while IFTT2 is the beta subunit.

The defect in IFT has been implicated in various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of cognitive and motor functions, as well as the accumulation of neurofibrillary tangles and neurodegenerate changes in the brain. The misfolding of IFT has been proposed as a potential cause of these disorders, which could lead to the accumulation of misfolded IFT protein in the brain and the development of neurofibrillary tangles and neurodegenerate changes.

IFT has also been implicated in myopathies, such as dystonia and Huntington's disease. These disorders are characterized by the progressive loss of motor and cognitive functions, as well as the accumulation of neurofibrillary tangles in the brain. The misfolding of IFT has been proposed as a potential cause of these disorders, which could lead to the accumulation of misfolded IFT protein in the brain and the development of neurofibrillary tangles.

IFT has also been implicated in cancer, including neuroendocrine carcinomas. These disorders are characterized by the progressive loss of motor and cognitive functions, as well as the accumulation of neurofibrillary tangles in the brain. The misfolding of IFT has been proposed as a potential cause of these disorders, which could lead to the accumulation of misfolded IFT protein in the brain and the development of neurofibrillary tangles.

Despite the significant clinical significance of IFT, the study of its dysfunction and misfolding mechanisms remains an ongoing challenge. Therefore, the development of a potential drug target and biomarker for IFT is of great interest.

IFT172 as a Drug Target

IFT172 has been identified as a potential drug target due to its unique structure and its involvement in various diseases. IFT172 is a transmembrane protein that consists of two subunits, IFTT1 and IFTT2. It plays a vital role in the transport of mitochondrial organelles, including the endoplasmic reticulum, to the cytoplasm. The misfolding of IFT has been implicated in various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, IFT172 could be a promising candidate for a drug target.

IFT172 has been shown to interact with various drug targets, including the protein Parkin, which is a key protein for the transport of dopamine to the brain. The interaction between IFT172 and Parkin suggests that IFT172 may play a role in the transport of other molecules to the brain, including neurotransmitters and hormones. Therefore, IFT172 could be a potential drug target for the treatment of neurodegenerative disorders.

IFT172 has also been shown to interact with the

Protein Name: Intraflagellar Transport 172

Functions: Required for the maintenance and formation of cilia. Plays an indirect role in hedgehog (Hh) signaling, cilia being required for all activity of the hedgehog pathway (By similarity)

The "IFT172 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFT172 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets